Borealis Bio's Nicergoline Active Pharmaceutical Ingredient (API) Awarded The European CEP Certificate

Jan 28, 2026

Leave a message

Recently, Borui Biopharmaceutical (Suzhou) Co., Ltd. (hereinafter referred to as the "Company") has received the Certificate of Suitability (CEP) to the European Pharmacopoeia (hereinafter referred to as "CEP") issued by the European Directorate for the Quality of Medicines & HealthCare (hereinafter referred to as "EDQM") for its nicergoline active pharmaceutical ingredient (API). We hereby announce the relevant information as follows:

I. Basic Information of the Drug

Name of chemical API: Nicergoline/NICERGOLINEManufacturer/Holder of the drug: Borui Biopharmaceutical (Suzhou) Co., Ltd.Certificate No.: CEP 2023-311-Rev 00Issuing authority: European Directorate for the Quality of Medicines & HealthCare (EDQM)Validity period: Valid for five years starting from February 1, 2024

II. Other Relevant Information of the Drug

Nicergoline is indicated for the treatment of senile dementia, vascular migraine, transient cerebral ischemia, excessive platelet aggregation and macular degeneration. The Company submitted the CEP application for its nicergoline API to EDQM in August 2023 and obtained the CEP certificate on February 1, 2024.

Send Inquiry
Contact usif have any question

You can either contact us via phone, email or online form below. Our specialist will contact you back shortly.

Contact now!